The history of copyright's flagship drug presents a interesting case for investors in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the exclusivity lapse and the subsequent arrival of off-brand versions have considerably affected earnings. This poses questions about the long-term viability of analogous the… Read More